Prior studies have demonstrated its high accuracy compared to amyloid and tau PET (3) and CSF biomarker status (28), its ability to detect p-Tau 217 elevation early in the AD process (3), and its superior performance over p-Tau 181 and p-Tau 231 (28, 33). The gene discussed is MAPT; the disease is Alzheimer disease.